Key Takeaways
- • Endovascular Engineering raised an oversubscribed $80 million Series C co-led by Gilde Healthcare and Norwest, marking a significant financing milestone for the commercial-stage medical device company.
- • The round attracted participation from six existing investors (Sante Ventures, 415 Capital, S3 Ventures, Panakes Partners, M&L Healthcare Investments, and two undisclosed strategic investors) plus a new global strategic investor, demonstrating broad institutional confidence.
- • The company focuses on venous thromboembolism (VTE) treatment, a cardiovascular condition affecting hundreds of thousands of patients annually and representing a substantial addressable market in interventional medicine.
- • Oversubscription of the round signals strong investor demand for Endovascular Engineering's technology and commercial trajectory at the medical device stage.
Summary
Endovascular Engineering, a commercial-stage medical technology company headquartered in Menlo Park, California, announced the closing of an $80 million Series C financing on April 13, 2026. The round was co-led by Gilde Healthcare and Norwest, two established healthcare-focused investment firms with deep expertise in medical devices and life sciences.
The financing was notably oversubscribed, indicating demand from investors exceeded the capital being raised. In addition to the lead investors, the round drew participation from a substantial investor syndicate including six existing backers: Sante Ventures, 415 Capital, S3 Ventures, Panakes Partners, and M&L Healthcare Investments, alongside two previously undisclosed strategic investors. A new global strategic investor also joined the round, expanding the company's institutional shareholder base.
Endovascular Engineering's commercial focus centers on the treatment of venous thromboembolism (VTE), a serious cardiovascular condition characterized by blood clot formation in the venous system. VTE encompasses deep vein thrombosis and pulmonary embolism, conditions affecting hundreds of thousands of patients in the United States annually and representing a significant clinical and economic burden. The company's positioning as commercial-stage indicates it has moved beyond development and has initiated revenue-generating operations with its VTE-focused therapeutic platform.
The $80 million Series C financing reflects investor confidence in the company's market opportunity, technology differentiation, and commercial execution. For institutional investors and hedge fund managers tracking the medical device and interventional cardiology sectors, this raise underscores continued capital deployment into specialized vascular treatment technologies addressing high-prevalence conditions with meaningful clinical outcomes and reimbursement potential.
The financing was notably oversubscribed, indicating demand from investors exceeded the capital being raised. In addition to the lead investors, the round drew participation from a substantial investor syndicate including six existing backers: Sante Ventures, 415 Capital, S3 Ventures, Panakes Partners, and M&L Healthcare Investments, alongside two previously undisclosed strategic investors. A new global strategic investor also joined the round, expanding the company's institutional shareholder base.
Endovascular Engineering's commercial focus centers on the treatment of venous thromboembolism (VTE), a serious cardiovascular condition characterized by blood clot formation in the venous system. VTE encompasses deep vein thrombosis and pulmonary embolism, conditions affecting hundreds of thousands of patients in the United States annually and representing a significant clinical and economic burden. The company's positioning as commercial-stage indicates it has moved beyond development and has initiated revenue-generating operations with its VTE-focused therapeutic platform.
The $80 million Series C financing reflects investor confidence in the company's market opportunity, technology differentiation, and commercial execution. For institutional investors and hedge fund managers tracking the medical device and interventional cardiology sectors, this raise underscores continued capital deployment into specialized vascular treatment technologies addressing high-prevalence conditions with meaningful clinical outcomes and reimbursement potential.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.